Home › Companies › Avadel Pharmaceuticals Plc › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Avadel Pharmaceuticals Plc’s Form 8-K, filed August 1, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of July 30, 2024: 9 items on Avadel Pharmaceuticals Plc’s Form 8-K, filed August 1, 2024: 1 approved · 8 passed (calculated).
Notable dissent: 1 director (10.4% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2024-2025 2025-2026
Explore Avadel Pharmaceuticals Plc in the interactive database Compare manager voting policies
These tallies are Avadel Pharmaceuticals Plc’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed August 1, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Gregory J. Divis | 48,809,808 | 4,581,316 | -- | 37,580 | 18,770,680 | 91% | Passed (calculated) | — |
| Elect Director: Dr. Eric J. Ende | 47,813,619 | 5,572,208 | -- | 42,877 | 18,770,680 | 90% | Passed (calculated) | — |
| Elect Director: Geoffrey M. Glass | 48,119,067 | 5,266,257 | -- | 43,380 | 18,770,680 | 90% | Passed (calculated) | — |
| Elect Director: Dr. Mark A. McCamish | 48,811,358 | 4,576,847 | -- | 40,499 | 18,770,680 | 91% | Passed (calculated) | — |
| Elect Director: Linda S. Palczuk | 48,128,173 | 5,258,040 | -- | 42,491 | 18,770,680 | 90% | Passed (calculated) | — |
| Elect Director: Peter J. Thornton | 48,823,282 | 4,562,281 | -- | 43,141 | 18,770,680 | 91% | Passed (calculated) | — |
| Elect Director: Dr. Naseem S. Amin | 48,738,654 | 4,646,143 | -- | 43,907 | 18,770,680 | 91% | Passed (calculated) | — |
| 2. To ratify, on a non-binding advisory basis, the appointment of Deloitte & Touche LLP as the Company's independent registered public auditor and accounting firm for the fiscal year ending December 31, 2024, and to authorize, in a binding vote, the Audit Comm | 70,739,385 | 1,299,493 | 160,506 | -- | 0 | 98% | Passed (calculated) | — |
| 3. To approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company as disclosed in the Proxy Statement | 47,961,536 | 5,105,188 | 361,980 | -- | 18,770,680 | 90% | Approved | — |
Source: Avadel Pharmaceuticals Plc, Form 8-K, filed with the SEC on August 1, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
134 asset managers disclosed a vote on at least one Avadel Pharmaceuticals Plc item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 2 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Prior year: 99.0% for (August 1, 2023 meeting) ▼ 9.5 pts
Description as filed by funds: Election of Directors: Dr. Eric J. Ende
Avadel Pharmaceuticals Plc’s own tally for this item (“Elect Director: Dr. Eric J. Ende”): 47,813,619 for, 5,572,208 against, per its Form 8-K filed August 1, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 19 asset managers below reported 5,804,656 for, 7,875 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JANUS INVESTMENT FUND | 4,629,164 | 0 | 0 | 0 | For |
| DWS | 421,000 | 0 | 0 | 0 | For |
| BRANDES INVESTMENT TRUST | 273,202 | 0 | 0 | 0 | For |
| Lord Abbett | 85,516 | 0 | 0 | 0 | For |
| Russell Investments | 63,365 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 62,753 | 0 | 0 | 0 | For |
| Fidelity | 45,690 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 42,258 | 0 | 0 | 0 | For |
| Royce | 35,460 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 34,030 | 0 | 0 | 0 | For |
| AdvisorShares Trust | 31,765 | 0 | 0 | 0 | For |
| Equitable | 30,640 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 21,626 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 12,677 | 0 | 0 | 0 | For |
| Empower | 8,120 | 0 | 0 | 0 | For |
| ProShares | 5,893 | 0 | 0 | 0 | For |
| BlackRock | 0 | 4,190 | 0 | 0 | Against |
| State Street | 0 | 3,685 | 0 | 0 | Against |
| Portside Wealth Group, LLC | 1,497 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Prior year: 99.9% for (August 1, 2023 meeting) ▼ 8.5 pts
Description as filed by funds: Election of Directors: Dr. Mark A. McCamish
Avadel Pharmaceuticals Plc’s own tally for this item (“Elect Director: Dr. Mark A. McCamish”): 48,811,358 for, 4,576,847 against, per its Form 8-K filed August 1, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 19 asset managers below reported 5,812,531 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JANUS INVESTMENT FUND | 4,629,164 | 0 | 0 | 0 | For |
| DWS | 421,000 | 0 | 0 | 0 | For |
| BRANDES INVESTMENT TRUST | 273,202 | 0 | 0 | 0 | For |
| Lord Abbett | 85,516 | 0 | 0 | 0 | For |
| Russell Investments | 63,365 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 62,753 | 0 | 0 | 0 | For |
| Fidelity | 45,690 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 42,258 | 0 | 0 | 0 | For |
| Royce | 35,460 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 34,030 | 0 | 0 | 0 | For |
| AdvisorShares Trust | 31,765 | 0 | 0 | 0 | For |
| Equitable | 30,640 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 21,626 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 12,677 | 0 | 0 | 0 | For |
| Empower | 8,120 | 0 | 0 | 0 | For |
| ProShares | 5,893 | 0 | 0 | 0 | For |
| BlackRock | 4,190 | 0 | 0 | 0 | For |
| State Street | 3,685 | 0 | 0 | 0 | For |
| Portside Wealth Group, LLC | 1,497 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Dr. Naseem S. Amin
Avadel Pharmaceuticals Plc’s own tally for this item (“Elect Director: Dr. Naseem S. Amin”): 48,738,654 for, 4,646,143 against, per its Form 8-K filed August 1, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 19 asset managers below reported 5,812,531 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JANUS INVESTMENT FUND | 4,629,164 | 0 | 0 | 0 | For |
| DWS | 421,000 | 0 | 0 | 0 | For |
| BRANDES INVESTMENT TRUST | 273,202 | 0 | 0 | 0 | For |
| Lord Abbett | 85,516 | 0 | 0 | 0 | For |
| Russell Investments | 63,365 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 62,753 | 0 | 0 | 0 | For |
| Fidelity | 45,690 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 42,258 | 0 | 0 | 0 | For |
| Royce | 35,460 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 34,030 | 0 | 0 | 0 | For |
| AdvisorShares Trust | 31,765 | 0 | 0 | 0 | For |
| Equitable | 30,640 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 21,626 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 12,677 | 0 | 0 | 0 | For |
| Empower | 8,120 | 0 | 0 | 0 | For |
| ProShares | 5,893 | 0 | 0 | 0 | For |
| BlackRock | 4,190 | 0 | 0 | 0 | For |
| State Street | 3,685 | 0 | 0 | 0 | For |
| Portside Wealth Group, LLC | 1,497 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Prior year: 99.5% for (August 1, 2023 meeting) ▼ 9.4 pts
Description as filed by funds: Election of Directors: Geoffrey M. Glass
Avadel Pharmaceuticals Plc’s own tally for this item (“Elect Director: Geoffrey M. Glass”): 48,119,067 for, 5,266,257 against, per its Form 8-K filed August 1, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 19 asset managers below reported 5,808,341 for, 4,190 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JANUS INVESTMENT FUND | 4,629,164 | 0 | 0 | 0 | For |
| DWS | 421,000 | 0 | 0 | 0 | For |
| BRANDES INVESTMENT TRUST | 273,202 | 0 | 0 | 0 | For |
| Lord Abbett | 85,516 | 0 | 0 | 0 | For |
| Russell Investments | 63,365 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 62,753 | 0 | 0 | 0 | For |
| Fidelity | 45,690 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 42,258 | 0 | 0 | 0 | For |
| Royce | 35,460 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 34,030 | 0 | 0 | 0 | For |
| AdvisorShares Trust | 31,765 | 0 | 0 | 0 | For |
| Equitable | 30,640 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 21,626 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 12,677 | 0 | 0 | 0 | For |
| Empower | 8,120 | 0 | 0 | 0 | For |
| ProShares | 5,893 | 0 | 0 | 0 | For |
| BlackRock | 0 | 4,190 | 0 | 0 | Against |
| State Street | 3,685 | 0 | 0 | 0 | For |
| Portside Wealth Group, LLC | 1,497 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Prior year: 99.8% for (August 1, 2023 meeting) ▼ 8.3 pts
Description as filed by funds: Election of Directors: Gregory J. Divis
Avadel Pharmaceuticals Plc’s own tally for this item (“Elect Director: Gregory J. Divis”): 48,809,808 for, 4,581,316 against, per its Form 8-K filed August 1, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 19 asset managers below reported 5,812,531 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JANUS INVESTMENT FUND | 4,629,164 | 0 | 0 | 0 | For |
| DWS | 421,000 | 0 | 0 | 0 | For |
| BRANDES INVESTMENT TRUST | 273,202 | 0 | 0 | 0 | For |
| Lord Abbett | 85,516 | 0 | 0 | 0 | For |
| Russell Investments | 63,365 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 62,753 | 0 | 0 | 0 | For |
| Fidelity | 45,690 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 42,258 | 0 | 0 | 0 | For |
| Royce | 35,460 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 34,030 | 0 | 0 | 0 | For |
| AdvisorShares Trust | 31,765 | 0 | 0 | 0 | For |
| Equitable | 30,640 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 21,626 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 12,677 | 0 | 0 | 0 | For |
| Empower | 8,120 | 0 | 0 | 0 | For |
| ProShares | 5,893 | 0 | 0 | 0 | For |
| BlackRock | 4,190 | 0 | 0 | 0 | For |
| State Street | 3,685 | 0 | 0 | 0 | For |
| Portside Wealth Group, LLC | 1,497 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Prior year: 99.9% for (August 1, 2023 meeting) ▼ 9.7 pts
Description as filed by funds: Election of Directors: Linda S. Palczuk
Avadel Pharmaceuticals Plc’s own tally for this item (“Elect Director: Linda S. Palczuk”): 48,128,173 for, 5,258,040 against, per its Form 8-K filed August 1, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 19 asset managers below reported 5,808,341 for, 4,190 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JANUS INVESTMENT FUND | 4,629,164 | 0 | 0 | 0 | For |
| DWS | 421,000 | 0 | 0 | 0 | For |
| BRANDES INVESTMENT TRUST | 273,202 | 0 | 0 | 0 | For |
| Lord Abbett | 85,516 | 0 | 0 | 0 | For |
| Russell Investments | 63,365 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 62,753 | 0 | 0 | 0 | For |
| Fidelity | 45,690 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 42,258 | 0 | 0 | 0 | For |
| Royce | 35,460 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 34,030 | 0 | 0 | 0 | For |
| AdvisorShares Trust | 31,765 | 0 | 0 | 0 | For |
| Equitable | 30,640 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 21,626 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 12,677 | 0 | 0 | 0 | For |
| Empower | 8,120 | 0 | 0 | 0 | For |
| ProShares | 5,893 | 0 | 0 | 0 | For |
| BlackRock | 0 | 4,190 | 0 | 0 | Against |
| State Street | 3,685 | 0 | 0 | 0 | For |
| Portside Wealth Group, LLC | 1,497 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Prior year: 99.8% for (August 1, 2023 meeting) ▼ 8.4 pts
Description as filed by funds: Election of Directors: Peter J. Thornton
Avadel Pharmaceuticals Plc’s own tally for this item (“Elect Director: Peter J. Thornton”): 48,823,282 for, 4,562,281 against, per its Form 8-K filed August 1, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 19 asset managers below reported 5,812,531 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JANUS INVESTMENT FUND | 4,629,164 | 0 | 0 | 0 | For |
| DWS | 421,000 | 0 | 0 | 0 | For |
| BRANDES INVESTMENT TRUST | 273,202 | 0 | 0 | 0 | For |
| Lord Abbett | 85,516 | 0 | 0 | 0 | For |
| Russell Investments | 63,365 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 62,753 | 0 | 0 | 0 | For |
| Fidelity | 45,690 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 42,258 | 0 | 0 | 0 | For |
| Royce | 35,460 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 34,030 | 0 | 0 | 0 | For |
| AdvisorShares Trust | 31,765 | 0 | 0 | 0 | For |
| Equitable | 30,640 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 21,626 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 12,677 | 0 | 0 | 0 | For |
| Empower | 8,120 | 0 | 0 | 0 | For |
| ProShares | 5,893 | 0 | 0 | 0 | For |
| BlackRock | 4,190 | 0 | 0 | 0 | For |
| State Street | 3,685 | 0 | 0 | 0 | For |
| Portside Wealth Group, LLC | 1,497 | 0 | 0 | 0 | For |
Combines 9 wordings of this item as funds reported it.
90% Approved · of votes cast
Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company.
Avadel Pharmaceuticals Plc’s own tally for this item (“3. To approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company as disclosed in the Proxy Statement”): 47,961,536 for, 5,105,188 against — passed, per its Form 8-K filed August 1, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3: To approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company as disclosed in the Proxy Statement.”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JANUS INVESTMENT FUND | 4,629,164 | 0 | 0 | 0 | For |
| DWS | 421,000 | 0 | 0 | 0 | For |
| BRANDES INVESTMENT TRUST | 273,202 | 0 | 0 | 0 | For |
| Lord Abbett | 85,516 | 0 | 0 | 0 | For |
| Russell Investments | 63,365 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 62,753 | 0 | 0 | 0 | For |
| Fidelity | 45,690 | 0 | 0 | 0 | For |
| RBB Fund Trust | 45,054 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 42,258 | 0 | 0 | 0 | For |
| Royce | 35,460 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 34,030 | 0 | 0 | 0 | For |
| AdvisorShares Trust | 31,765 | 0 | 0 | 0 | For |
| Equitable | 30,640 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 21,626 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 12,677 | 0 | 0 | 0 | For |
| Empower | 8,120 | 0 | 0 | 0 | For |
| ProShares | 5,893 | 0 | 0 | 0 | For |
| BlackRock | 4,190 | 0 | 0 | 0 | For |
| State Street | 3,685 | 0 | 0 | 0 | For |
Fund voting reports, all 19 managers: 5,856,088 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Janus Henderson | 12,815,946 | 0 | 0 | 0 | For |
| GENDELL JEFFREY L | 0 | 5,740,143 | 0 | 0 | Against |
| Vivo Capital, LLC | 3,972,099 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 2,776,539 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 1,397,507 | 0 | 0 | 0 | For |
| UniSuper Management Pty Ltd | 948,907 | 0 | 0 | 0 | For |
| Woodline Partners LP | 926,109 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 883,247 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 664,738 | 0 | 0 | 0 | For |
| BRANDES INVESTMENT PARTNERS, LP | 659,931 | 0 | 0 | 0 | For |
| Tri Locum Partners LP | 592,699 | 0 | 0 | 0 | For |
| KENNEDY CAPITAL MANAGEMENT LLC | 541,272 | 0 | 0 | 0 | For |
| Soleus Capital Management, L.P. | 478,255 | 0 | 0 | 0 | For |
| NEW YORK STATE COMMON RETIREMENT FUND | 445,191 | 0 | 0 | 0 | For |
| Utah Retirement Systems | 410,284 | 0 | 0 | 0 | For |
| Samsara BioCapital, LLC | 384,784 | 0 | 0 | 0 | For |
| Goldman Sachs | 351,760 | 0 | 0 | 0 | For |
| Knott David M Jr | 333,000 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 294,077 | 0 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 287,008 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 0 | 280,000 | 0 | Abstain |
| Obermeyer Wealth Partners | 279,494 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 248,125 | 0 | 0 | 0 | For |
| LORD, ABBETT & CO. LLC | 232,298 | 0 | 0 | 0 | For |
| Citadel | 230,928 | 0 | 0 | 0 | For |
Institutional-manager reports, all 118 managers: 32,094,720 for, 5,760,293 against, 285,686 abstained. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Prior year: 99.8% for (August 1, 2023 meeting) ▼ 1.6 pts
Description as filed by funds: To ratify, on a non-binding advisory basis, the appointment of Deloitte & Touche LLP as the Company's independent registered public auditor and accounting firm for the fiscal year ending December 31, 2024, and to authorize, in a binding vote, the Audit Committee of the Board of Directors to set the independent registered public auditor and accounting firm remuneration
Avadel Pharmaceuticals Plc’s own tally for this item (“2. To ratify, on a non-binding advisory basis, the appointment of Deloitte & Touche LLP as the Company's independent registered public auditor and accounting firm for the fiscal year ending December 31, 2024, and to auth”): 70,739,385 for, 1,299,493 against, per its Form 8-K filed August 1, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 20 asset managers below reported 5,857,585 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JANUS INVESTMENT FUND | 4,629,164 | 0 | 0 | 0 | For |
| DWS | 421,000 | 0 | 0 | 0 | For |
| BRANDES INVESTMENT TRUST | 273,202 | 0 | 0 | 0 | For |
| Lord Abbett | 85,516 | 0 | 0 | 0 | For |
| Russell Investments | 63,365 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 62,753 | 0 | 0 | 0 | For |
| Fidelity | 45,690 | 0 | 0 | 0 | For |
| RBB Fund Trust | 45,054 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 42,258 | 0 | 0 | 0 | For |
| Royce | 35,460 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 34,030 | 0 | 0 | 0 | For |
| AdvisorShares Trust | 31,765 | 0 | 0 | 0 | For |
| Equitable | 30,640 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 21,626 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 12,677 | 0 | 0 | 0 | For |
| Empower | 8,120 | 0 | 0 | 0 | For |
| ProShares | 5,893 | 0 | 0 | 0 | For |
| BlackRock | 4,190 | 0 | 0 | 0 | For |
| State Street | 3,685 | 0 | 0 | 0 | For |
| Portside Wealth Group, LLC | 1,497 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 96,204,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | JANUS INVESTMENT FUND | 4.81% |
| 2 | DWS | 0.44% |
| 3 | BRANDES INVESTMENT TRUST | 0.28% |
| 4 | Lord Abbett | 0.09% |
| 5 | Russell Investments | 0.07% |
| 6 | DRIEHAUS MUTUAL FUNDS | 0.07% |
| 7 | Fidelity | 0.05% |
| 8 | RBB Fund Trust | 0.05% |
| 9 | PENN SERIES FUNDS INC | 0.04% |
| 10 | Royce | 0.04% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Janus Henderson | 13.32% |
| 2 | GENDELL JEFFREY L | 5.97% |
| 3 | Vivo Capital, LLC | 4.13% |
| 4 | BRAIDWELL LP | 2.89% |
| 5 | RTW INVESTMENTS, LP | 1.45% |
| 6 | UniSuper Management Pty Ltd | 0.99% |
| 7 | Woodline Partners LP | 0.96% |
| 8 | MPM BioImpact LLC | 0.92% |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 0.69% |
| 10 | BRANDES INVESTMENT PARTNERS, LP | 0.69% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 5,453,526 | 5.67% | Form 13F, quarter ended March 31, 2025 |
| Jeffrey L. Gendell | 4,839,357 | 5.03% | Schedule 13G, filed February 6, 2026 |
| Vanguard Group | 3,904,650 | 4.06% | Form 13F, quarter ended March 31, 2025 |
| Citadel Advisors | 2,409,110 | 2.50% | Form 13F, quarter ended March 31, 2025 |
| JANUS HENDERSON GROUP PLC | 1,823,865 | 1.90% | Schedule 13G, filed February 17, 2026 |
| State Street | 1,659,306 | 1.72% | Form 13F, quarter ended March 31, 2025 |
| Geode Capital | 1,189,596 | 1.24% | Form 13F, quarter ended March 31, 2025 |
| Morgan Stanley | 1,034,614 | 1.08% | Form 13F, quarter ended March 31, 2025 |
| Goldman Sachs | 727,869 | 0.76% | Form 13F, quarter ended March 31, 2025 |
| Northern Trust | 639,866 | 0.67% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 96,204,000 shares outstanding, as reported by Avadel Pharmaceuticals Plc on its Form 10-Q dated June 30, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Avadel Pharmaceuticals Plc's shareholder meeting held July 30, 2024, in the 2024-2025 proxy season, 134 asset managers reported votes on at least one of its 9 ballot items in their SEC Form N-PX filings, covering 349 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of the named executive officers… — Avadel Pharmaceuticals Plc's filing reports the proposal as approved, with 90% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Avadel Pharmaceuticals Plc's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on August 1, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Avadel Pharmaceuticals Plc’s 10-Q dated June 30, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Avadel Pharmaceuticals Plc proxy season coverage: 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “Avadel Pharmaceuticals Plc 2024 Annual Meeting (2024-2025 season)”, https://proxyvotesnow.com/company/avadel-pharmaceuticals-plc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.